Hookipa Pharma Inc

HOOKIPA Pharma, Inc. engages in the development of immunotherapeutics, targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. Its product includes VaxWace and TheraT. The company was founded by Rolf Zinkernagel, Andreas Bergthaler, Lukas Flatz, Katherine Cohen, and Daniel Pinschewer in 2011 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

HOOKIPA Pharma, Inc. is a clinical stage biopharmaceutical company, which engages in developing pharmaceutical products to prevent and cure infectious diseases and cancer. The firm also focuses on immunotherapeutics based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. The company was founded by Rolf M. Zinkernagel, Andreas Bergthaler, Lukas Flatz, and Daniel D. Pinschewer in 2011 and is headquartered in New York, NY.

Hookipa (NASDAQ: HOOK ) stock is rocketing higher on Thursday after reaching a strategic collaboration and license agreement with Roche (OTCMKTS: RHHBF ). That agreement has the two companies working together on the development of HB-700 and a second unnamed novel arenaviral immunotherapy.

Why Is Hookipa (HOOK) Stock Up 26% Today?

NEW YORK and VIENNA, Oct. 20, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapies based on its proprietary arenavirus platform, announced today a strategic collaboration and license agreement with Roche to develop HB-700 for KRAS-mutated cancers and a second undisclosed novel arenaviral immunotherapy. This represents HOOKIPA's first oncology licensing collaboration.

HOOKIPA announces strategic collaboration and license agreement with Roche to develop novel arenaviral immunotherapy for KRAS-mutated cancers

HOOKIPA Pharma Inc. (HOOK) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

HOOKIPA Pharma Inc. (HOOK) Upgraded to Buy: What Does It Mean for the Stock?

NEW YORK and VIENNA, Sept. 07, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapies based on its proprietary arenavirus platform, today announced that HOOKIPA's management team will participate in the following upcoming investor conferences:

HOOKIPA Pharma to Participate in Upcoming Investor Conferences in September

HOOKIPA Pharma Inc. (HOOK) delivered earnings and revenue surprises of 36.11% and 21.43%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

HOOKIPA Pharma Inc. (HOOK) Reports Q2 Loss, Misses Revenue Estimates

NEW YORK and VIENNA, Austria, Aug. 11, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapies based on its proprietary arenavirus platform, today reported financial results for the second quarter of 2022 and Company updates.

HOOKIPA Pharma Reports Second Quarter 2022 Financial Results and Corporate Updates

NEW YORK and VIENNA, Austria, Aug. 04, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapies based on its proprietary arenavirus platform, today announced that it will release its second quarter 2022 financial results and Company update before the market open on Thursday, August 11, 2022.

HOOKIPA Pharma to Report Second Quarter 2022 Financial Results on August 11, 2022

NEW YORK and VIENNA, Austria, July 25, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapies based on its proprietary arenavirus platform, has received U.S. Food and Drug Administration (FDA) acceptance of its Investigational New Drug (IND) application for HB-300, a novel arenaviral immunotherapy for the treatment of metastatic castration-resistant prostate cancer.

FDA accepts HOOKIPA's Investigational New Drug Application for HB-300 for the treatment of metastatic castration-resistant prostate cancer

NEW YORK and VIENNA, Austria, June 21, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced several leadership changes as the company expands its clinical development and pipeline programs. All new appointments are effective July 1, 2022.

HOOKIPA Announces Executive Leadership Changes

NEW YORK and VIENNA, Austria, June 09, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that the company will participate in investor meetings at the JMP Securities Life Sciences Conference being held in New York City, June 15 - 16, 2022.

HOOKIPA to Participate in the JMP Securities Life Sciences Conference

NEW YORK and VIENNA, Austria, June 05, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced positive Phase 1 results from its HB-200 program evaluating single-vector HB-201 and alternating 2-vector HB-202/HB-201 in advanced Human Papillomavirus 16-positive (HPV16+) head and neck cancer patients. HB-200 was generally well tolerated, rapidly induced a high magnitude of tumor-specific T cells and showed early anti-tumor activity in these difficult-to-treat patients. The company also announced the recommended Phase 2 dose for alternating 2-vector HB-202/HB-201, which showed superior immune and tumor response compared to single-vector HB-201. The data were presented in a poster presentation (abstract #2517) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.

HOOKIPA announces positive Phase 1 data and Phase 2 plans for HB-200 program for the treatment of advanced head and neck cancers at ASCO

NEW YORK and VIENNA, Austria, June 03, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, announced preclinical data, in collaboration with Gilead Sciences, Inc., on arenaviral therapeutic vaccines that are being studied as a component of a potential functional curative regimen for human immunodeficiency virus (HIV). These data presented at the Keystone Symposium: Progress in Vaccine Development for Infectious Disease in Breckenridge, Colorado highlight robust and high-quality immune responses following administration of replicating arenaviral therapeutic vaccines.

Preclinical Data on Novel Arenaviral HIV Therapeutic Vaccines Presented at Keystone Symposium

NEW YORK and VIENNA, Austria, May 26, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that complete HB-200 Phase 1 results (NCT04180215) for single-vector HB-201 and alternating 2-vector HB-202/HB-201 in patients with advanced Human Papillomavirus 16-positive (HPV16+) cancers, including the recommended Phase 2 dose for HB-202/HB-201, will be shared in a poster presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place June 3-7, 2022. Data as of March 31, 2022 will be presented on 68 patients, 54 of whom had head and neck squamous cell carcinoma (HNSCC).

HOOKIPA to Present Complete HB-200 Phase 1 Results and Recommended Phase 2 Dose for HB-202/HB-201 for the Treatment of Advanced HPV16+ Cancers at ASCO

NEW YORK and VIENNA, Austria, May 16, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today reported financial results and business highlights for the first quarter of 2022.

HOOKIPA Pharma Reports First Quarter 2022 Financial Results and Recent Highlights

NEW YORK and VIENNA, Austria, May 09, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that it will release first quarter 2022 financial results before the market open on Monday, May 16, 2022.

HOOKIPA Pharma to Report First Quarter 2022 Financial Results on May 16, 2022

NEW YORK and VIENNA, Austria, May 02, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced the promotion of Christine D. Baker to Chief Operating Officer effective immediately. Christine joined HOOKIPA in August 2019 as Chief Business Officer and has played a critical role in securing several strategic business collaborations for HOOKIPA's novel arenaviral immunotherapeutics that help position the science and the company for continued growth.

HOOKIPA announces promotion of Christine D. Baker to Chief Operating Officer

NEW YORK and VIENNA, Austria, April 20, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced the appointment of Tim Reilly, Ph.D. to its Board of Directors, effective immediately.

HOOKIPA Pharma Appoints Tim Reilly, Ph.D. to its Board of Directors

HOOKIPA Pharma Inc (NASDAQ: HOOK) has announced preclinical data demonstrating potent T cell responses, combination use beyond PD-1 inhibitors, and the ability to break immune tolerance to various self-antigens for targeting cancers.  Preclinical data show that combining co-.

Hookipa Shares Jump On New Preclinical Data On Cancer Immunotherapies

NEW YORK and VIENNA, Austria, April 13, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced positive preclinical data demonstrating potent T cell responses, potential novel combination use beyond PD-1 inhibitors, and the ability to break immune tolerance to various self-antigens for targeting cancers. The results highlight the potential of HOOKIPA's novel arenaviral platform in difficult-to-treat cancers and as a backbone of potential combination therapies requiring robust T cell responses for cancer patients. The data were shared as poster presentations at the 2022 American Association for Cancer Research Annual Meeting (AACR).

New data show HOOKIPA's arenaviral immunotherapies induce potent T cell responses in novel combinations and against tumor self-antigens

NEW YORK and VIENNA, Austria, April 13, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that the company will participate in investor meetings at the Kempen Life Sciences Conference being held in Amsterdam, April 20 - 21, 2022.

HOOKIPA to Participate in the Kempen Life Sciences Conference

Several data readouts of HB-200 alone and in combination with KEYTRUDA for treatment of HPV16+ HNSCC patients are expected in 2022.

Hookipa: Speculative Biotech With Key Catalysts In 2022

HOOKIPA Pharma Inc. (HOOK) CEO Joern Aldag on Q4 2021 Results - Earnings Call Transcript

HOOKIPA Pharma Inc. (HOOK) delivered earnings and revenue surprises of -22.64% and 9.63%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

HOOKIPA Pharma Inc. (HOOK) Reports Q4 Loss, Misses Revenue Estimates

NEW YORK and VIENNA, Austria, March 24, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today reported financial results and provided a corporate update for the fourth quarter and full year 2021, as well as outlook for 2022.

HOOKIPA Reports Fourth Quarter and Full Year 2021 Financial Results and Provides 2022 Outlook

NEW YORK and VIENNA, Austria, March 22, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that Klaus Orlinger, Ph.D. has been promoted to Chief Scientific Officer. Since joining HOOKIPA in February 2012, Klaus has played a leading role in driving HOOKIPA's arenaviral platform to the clinic and demonstrating the potent antigen-specific T cell response these novel immunotherapies induce.

News for Hookipa Pharma Inc Stock (HOOK)